Podcasts about chorea

Chorea describes involuntary movements that are random, abrupt, and unpredictable, flowing from one body part to another. The most common cause of genetic chorea in adults is Huntington disease, which requires comprehensive, multidisciplinary care as well as support for care partners, who may themselves be diagnosed with the disease. In this episode, Aaron Berkowitz, MD, PhD FAAN speaks with Kathryn P. L. Moore, MD, MSc, author of the article “Huntington Disease and Chorea” in the Continuum® August 2025 Movement Disorders issue. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology at the University of California San Francisco in the Department of Neurology in San Francisco, California. Dr. Moore is an assistant professor and director of the Parkinson's Disease and Movement Disorders Fellowship in the department of neurology at Duke University in Durham, North Carolina. Additional Resources Read the article: Huntington Disease and Chorea Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @AaronLBerkowitz Guest: @KatiePMooreMD Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Berkowitz: This is Dr Aaron Berkowitz with Continuum Audio, and today I'm interviewing Dr Kathryn Moore about her article on diagnosis and management of Huntington disease and chorea, which appears in the August 2025 Continuum issue on movement disorders. Welcome to the podcast, Dr Moore. Could you please introduce yourself to our audience? Dr Moore: Yeah, thank you so much. I'm so excited to be here. I'm Dr Moore. I'm an assistant professor of neurology at Duke University, where I work as a movement disorder specialist. I run our fellowship there and help with our residency program as well. So, I'm excited to speak with our listeners about chorea today. Dr Berkowitz: Fantastic. And we're excited to talk to you about chorea. So, as a general neurologist myself, I only see chorea pretty rarely compared to other movement disorders like tremor, myoclonus, maybe the occasional tic disorder. And like anything I don't see very often, I always have to look up the differential diagnosis and how to evaluate a patient with chorea. So, I was so glad to read your article. And next time I see a patient with chorea, I know I'll be referring to your article as a great reference to have a framework for how to approach it. I hope our readers will look at all these helpful tables on differential diagnosis based on distribution of chorea in the body, potential etiologies, time course of onset and evolution, associated drug-induced causes, what tests to send. So, I highly recommend our listeners read the article. Keep those tables handy for when a patient comes in with chorea. I'm excited to pick your brain about some of these topics today. First, how do you go about distinguishing chorea from other hyperkinetic movement disorders when you see a patient that you think might have chorea? Dr Moore: One of the wonderful things about being a movement disorder specialist is we spend a lot of time looking at movements and training our brain to make these distinctions. The things that I would be looking out for chorea is involuntary, uncontrolled movements that appear to be brief and flowing from one part of the body to another. So, if you can watch a patient and predict what movements they're going to do, this probably isn't chorea. And it should be flowing from one part of the body to another. So, not staying just in one part of the body or having sustained movements. It can be difficult to distinguish between a tic or dystonia or myoclonus. Those things tend to be more predictable and repetitive than the chorea, which tends to be really random and can look like dancing. Dr Berkowitz: That's very helpful. So, once you've decided the patient has chorea, what's your framework for thinking about the differential diagnosis of the cause of the patient's chorea? Dr Moore: Well, that could be really challenging. The differential for chorea is very broad, and so the two things that I tend to use are age of the patient and acuity of onset. And so, if you're thinking about acute onset of chorea, you're really looking at a structural lesion like a stroke or a systemic issue like infection, hyperglycemia, etc. Where a gradually progressive chorea tends to be genetic in nature. When you're thinking about the difference between a child and an adult, the most common cause of chorea in a child is Sydenham's chorea. And actually, the most common cause of chorea that I tend to see is Parkinson's disease medication. So, if anybody's seen dyskinesia in Parkinson's disease, you've seen chorea. But it's those two things that I'm using, the age of the patient and the acuity. Somewhere in the middle, though---so, if you have subacute onset of chorea---it's important to remember to think about autoimmune conditions or paraneoplastic conditions because these are treatable. Dr Berkowitz: That's very helpful. So, like in any chief concern in neurology, we're using the context like the age and then the time course. And then a number of other helpful points in your article about the distribution of chorea in the body. Any comments you'd like to make about- we have this very helpful table that I thought was very interesting. So, you really get deep into the nuances of chorea and the movement disorder specialist expert level. Are there any aspects of parts of the body affected by chorea or distribution of chorea across the body that help you hone your differential diagnosis? Dr Moore: Certainly. I think where the chorea is located in the body can be helpful, but not as helpful as other conditions where you're localizing a lesion or that sort of thing. Because you can have a systemic cause of chorea that causes a hemichorea; that you can have hyperglycemia causing a hemichorea, or even Sydenham's chorea being a hemichorea. But things that we think about, if the forehead is involved, I would think about Huntington's disease, although this is not pathognomonic. And if it's involving the face or the mouth, you can think about neuroacanthocytosis or, more commonly, tardive dyskinesia. Hemichorea would make me think about some of those systemic issues like hyperglycemia, Sydenham's chorea, those sorts of things, but I would rely more on the historical context and the acuity of presentation than the distribution itself. Dr Berkowitz: Got it. That's very helpful. So those can be helpful features, but not sort of specific for any particular condition. Dr Moore: Exactly. Dr Berkowitz: Yeah, I often see forehead chorea mentioned as sort of specific to Huntington's disease. Since I don't see much Huntington's disease myself, what does forehead chorea look like? What is the forehead doing? How do you recognize that there is chorea of the forehead? It's just sort of hard for me to imagine what it would look like. Dr Moore: It's really tricky. I think seeing the eyebrows go up and down or the brows furrow in an unpredictable way is really what we're looking for. And that can be hard if you're having a conversation. My forehead is certainly animated as we're talking about one of my favorite topics here. One of the tricks that I use with the fellows is to observe the forehead from the side, and there you can see the undulation of the forehead muscles. And that can be helpful as you're looking for these things. I think where it's most helpful to use the forehead is if you're trying to determine if someone with a psychiatric history has tardive dyskinesia or Huntington's disease, because there can be quite a lot of overlap there. And unfortunately, patients can have both conditions. And so, using the forehead movement can be helpful to maybe direct further testing for Huntington's disease. Dr Berkowitz: Oh, wow, that's a very helpful pearl. So, if you see, sort of, diffuse chorea throughout the body and the forehead is involved, to my understanding it may be less specific. But in the context of wondering, is the neuropsychiatric condition and movement disorder related by an underlying cause in the case of seeing orofacial dyskinesias, is the relationship a drug having caused a tardive dyskinesia or is the whole underlying process Huntington's, the absence of forehead might push you a little more towards tardive dyskinesia, presuming there is an appropriate implicated drug and the presence of forehead chorea would really clue you in more to Huntington's. Did I understand that pearl? Dr Moore: That's exactly right, and I'm glad you brought up the point about making sure, if you're considering tardive dyskinesia, that there has been an appropriate drug exposure. Because without that you can't make that diagnosis. Dr Berkowitz: That's a very helpful and interesting pearl, looking at the forehead from the side. That is a movement disorders pearl for sure. Sort of not just looking at the forehead from one angle and trying to figure out what it's doing, but going to look at the patient in profile and trying to sort it out. I love that. Okay. So, based on the differential diagnosis you would have crafted based on whether this is sort of acute, subacute, chronic, the age of the patient, whether it's unilateral, bilateral, which parts of the body. How do you go about the initial evaluation in terms of laboratory testing, imaging, etc.? Dr Moore: Well, certainly in an acute-onset patient, you're going to get a number of labs---and that's listed out for you in the paper---and consider imaging as well, looking for an infarct. One thing our learners will know is that sort of the typical answer to what's the infarct causing hemichorea would be the subthalamic nucleus. But really, those infarcts can be almost anywhere. There are case reports for infarcts in a wide variety of places in the brain leading to hemichorea. So, I think some general blood work and an MRI of the brain is a good place to start. For someone who has a more chronic course of the development of chorea, there are certain labs that I would get---and an MRI, because if you get an MRI and there's heavy metal deposition or other disease, structurally, that indicates a certain condition, that can help you pretty considerably. But otherwise, I'm looking for inflammatory markers, heavy metals, HIV, some general other things that are outlined, to help make sure that I'm not missing something that's treatable before I go down the route of genetic testing. And we may talk about this in a little bit, but if you start out with genetic testing and then you sort of have to back up and do more systemic testing, that can be very disjointed when it comes to good patient care. Dr Berkowitz: That's very helpful. So yeah, if it's acute, obviously this is the most straightforward scenario, acute and unilateral. We're imagining something lesional, as you said, either a stroke or---not sort of sudden, but fast, but not sudden---you might think of another structural lesion. Toxoplasmosis, right, has an affinity for the basal ganglia if you were seeing this in a patient who is immunocompromised. But in a case that, probably as you alluded to, sort of what we would see most commonly in practice, those still relatively rare, sort of subacute to chronic symmetric chorea. There's a long list of tests that are recommended. In your article and in other texts, I've read lupus testing, anti-phospholipid antibodies… but the list is long. I'll refer readers to your article. Out of curiosity as a specialist, how often do you see any of these labs come back revealing any underlying diagnosis in a patient who's otherwise healthy and just has developed chorea and comes to you with that chief concern? I feel like I've sent that mega-workup a few times; I'm obviously a general neurologist, but not nearly as many times as you have been. It's- I can't remember a time where something has come up, maybe an ANA one to forty or something like this that we don't think is relevant. But in your practice, how often do you end up finding a reversible cause in the laboratory testing versus ending up starting to go down the genetic testing route, which we'll talk about in a moment? Dr Moore: It's not common, but it is important that we capture these things. Because for a lot of those laboratory tests, there are treatments that are available, or other health implications if those come back positive. So, the case I think of is a polycythemia vera patient who had diffused subacute onset chorea and was able to be treated, was temporarily managed with medication for her chorea, and as her PV improved, she was able to come off those medications. As I was alluding to before---and I'm sure we'll talk about genetic testing---if you test for HD and it's negative, do you go down the route of additional expensive genetic testing, or do you then circle back and go, oops, I missed this treatable condition? As we talk about genetic testing as well, getting HD testing is a pretty involved process. And so, we want to make sure we are checking all those boxes before we move forward. So, it's not common, but we do catch some treatable conditions, and that's really important not to miss. Dr Berkowitz: That's very interesting. So, you diagnosed that polycythemia vera by blood smear, is that how you make the diagnosis? Dr Moore: Yes. Dr Berkowitz: And is that a once-in-a-career-so-far type of thing, or does that happen time to time? Dr Moore: For me, that's a once-so-far, but I don't doubt that I'll see it again. Dr Berkowitz: Great. And how about lupus and some of these other things we look for in the absence of other systemic features? Have you picked up any of these or heard of colleagues picking up something on laboratory testing? They said, oh, this patient came in for a referral for genetic testing, negative Huntington's disease. And good news, we found polycythemia vera; good news, we found undiagnosed lupus and we reversed it. I'm just curious, epidemiologically, seeing these long lists and not having the subspecialty practice that you do, how often you find a reversible cause like we do for neuropathy all the time, right? Oh, it's diabetes, it's B12---maybe not reversible, but preventing progression---or reversible dementia work up. You get so excited when you find low B12 and you replete the patient's B12, and they get better when they had been concerned they were developing an irreversible condition. How often does one in your subspecialty find a reversible cause on that initial mega-lab screen? Dr Moore: I think it's really uncommon, and maybe the folks that do are caught by someone else that never make it to Huntington's clinic, but I don't tend to see those cases. There are, of course, case reports and well-described in the literature about lupus and movement disorders and things of that nature, but that doesn't come to our clinic on a regular basis for sure. Dr Berkowitz: Got it. That's helpful to hear. Well, we've alluded to genetic testing a number of times now, so let's go ahead and talk about it. A lot of your article focuses on Huntington disease, and I was thinking about---in the course of our medical training in medical school, and then neurology residency, for those of us who don't become movement disorder experts like yourself---we learn a lot about Huntington disease. That's sort of the disease that causes chorea, until we later learned there are a whole number of diseases, not just the reversible causes we've been talking about, but a number of genetic diseases which you expertly reviewing your article. So, what are some of the red flags that suggest to you that a patient with chronically progressive chorea---and whom you're concerned for Huntington's or another genetic cause---what are some things you notice about the history, about the exam, the symptoms, the signs, the syndrome, that suggest to you that, actually, this one looks like it might not turn out to be HD. I think this patient might have something else. And as you have alluded to, how do you approach this? Do you send HD testing, wait for it to come back, and then go forward? Are there genetic panels for certain genetic causes of chorea? Do you skip just a whole exome sequencing, or will you miss some of the trinucleotide repeat conditions? How do you approach this in practice? Dr Moore: I'll try to tackle all that. One thing I will say is that a lot of patients with chorea, regardless of the cause, can look very similar to one another. So, if you're looking at chronic onset chorea, perhaps with some neuropsychiatric features, I'm going to most often think about HD because that's the most common cause. Certainly, as we mentioned before, if there's a lot of tongue protrusion, I would think about the acanthocytic conditions, neurocanthocytosis and McCloud syndrome. But generally in those conditions, we're looking at HD as the most likely cause. Certainly, if there is epilepsy or some other syndromic types of things going on, I may think more broadly. But it's important to know that while HD, as you mentioned, is the cause of chorea, many of our patients will have parkinsonism, tics, dystonia, a whole host of other movement phenomenologies. So, that wouldn't dissuade me from thinking about HD. When we think about the kind of patients that you're describing, upwards of 95% of those people will have Huntington's disease. And the process for genetic testing is fairly involved. The Huntington's Disease Society of America has organized a set of recommendations for providers to go about the process of genetic testing in a safe and supportive way for patients and their families. And so that's referred to in the article because it really is important and was devised by patients and families that are affected by this disease. And so, when we're thinking about genetic testing for HD, if I reveal that you have HD, this potentially affects your children and your parents and your siblings. You can have a lot of implications for the lives and health and finances of your family members. We also know that there is high suicidality in patients with HD, in patients who are at risk for HD; and there's even a higher risk of suicidality in patients who are at risk but test negative for HD. So, we do recommend a supportive environment for these patients and their families. And so, for presymptomatic patients or patients who are at risk and don't have chorea, this involves making sure we have, sort of, our ducks in a row, as it were, when we think about life insurance, and, do you have somebody supportive to be with you through this journey of genetic testing, no matter what the results are? So, oftentimes I'll say to folks, you know, there's this 20-page policy that I encourage you to look at, but there are Huntington's Disease Centers of Excellence across the country that are happy to help you with that process, to make sure that the patients are well supported. This is an individual genetic test because, as you mentioned, it is a CAG repeat disorder. And unfortunately, there is no chorea panel. So, if an HD test comes back negative, what we'll do then is think about what's called the HD phenocopies. As I mentioned before, some of these patients who look like they have HD will have a negative HD test. And so, what do you do then? Well, there's a handful of phenocopies---so, other genetic mutations that cause a very similar presentation. And so, we try to be smart, since there's not a panel, we try to be smart about how we choose which test to do next. So, for instance, there's a condition called DRPLA that is present in an African-American family here in my area, in North Carolina, as well as in Japan. And so, if someone comes from those backgrounds, we may decide that that's the next test that we're going to do. If they are white European descent, we may consider a different genetic test; or if they're sub-Saharan African, we may choose a different one from that. However, even if you do a really thorough job, all those blood tests, all those genetic tests, you will occasionally get patients that you can't find a diagnosis for. And so, it's important to know even when you do a good job, you may still not find the answer. And so, I think trying to do things with this complex of the presentation in a systematic way for yourself so you're not missing something. So, going back to our answer about, how do I look at lupus and polycythemia vera and all of that, to think about it in a systematic way. That when you get to the end and you say, well, I don't have an answer, you know you've tried. Dr Berkowitz: That's very helpful to hear your approach to these challenging scenarios, and also how to approach the potential challenging diagnosis for patients and their families getting this diagnosis, particularly in the presymptomatic phase. And your article touches on this with a lot of nuance and thoughtfulness. So, I encourage our listeners to have a read of that section as well. So, last here, just briefly in our final moments, you discuss in your article the various symptomatic treatments for chorea. We won't have time to go into all the details of all the many treatments you discussed, but just briefly, how do you decide which medication to start in an individual patient with chorea for symptomatic management? What are some of the considerations related to the underlying condition, potential side effect profiles of the particular medications, or any other considerations just broadly, generally, as you think about choosing one of the many medications that can be used to treat chorea? Dr Moore: Certainly. So, there is a group of FDA-approved medications, VMAT2 inhibitors, that we can choose from, or the off-label use of neuroleptics. And so, there's a lot of things that go into that. Some of that is insurance and cost and that sort of thing, and that can play a role. Others are side effects. So, for the VMAT2 inhibitors, they all do have a black box warning from the FDA about suicidality. And so, if a patient does struggle with mental health, has a history of suicidality, psychiatric admissions for that sort of thing, then I would be more cautious about using that medication. All patients are counseled about that, as are their families, to help us give them good support. So, the neuroleptics do not tend to have that side effect and can help with mood as well as the chorea and can be helpful in that way. And some of them, of course, will have beneficial side effects. So, olanzapine may help with appetite, which can be important in this disease. So, the big considerations would be the black box warning and suicidality, as well as, are we trying to just treat chorea or are we treating chorea and neuropsychiatric issues? Dr Berkowitz: Fantastic. Thank you for that overview. And again, for our listeners, there's a lot more detail about all of these medications, how they work, how they're used in different patient populations, their side effects, etc, to be reviewed in your excellent article. Again, today, I've been interviewing Dr Kathryn Moore about her article on diagnosis and management of Huntington's disease in chorea, which appears in the August 2025 Continuum issue on movement disorders. Be sure to check out Continuum Audio episodes from this and other issues. And thank you so much to our listeners for joining today. And thank you again, Dr Moore. Dr Moore: Thanks for having me. Dr Monteith: This is Dr Teshamae Monteith, associate editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Auch mit einem erblichen Gendefekt empfindet David es als Privileg zu leben.

Auch mit einem erblichen Gendefekt empfindet David es als Privileg zu leben.

Profs. Elena Moro and Ruth Walker discuss the management of chorea, including when this is appropriate. They focus on Huntington's disease and the role of deep brain stimulation and other surgical interventions, in addition to medical management.

In this episode Iva Stankovic hosts Alessio Di Fonzo to discuss how to diagnose chorea and how to approach differential diagnosis to entangle the etiology of chorea.

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: December 6, 2018 You may be able to recognize chorea. But what does it make you think of besides Huntington disease? In this two-part series, we'll cover the clinical manifestations, differential diagnosis, and management of Huntington disease. In part 1, Dr. Travis Lewis (University of Pennsylvania) creates a framework for hyperkinetic movement disorders and Huntington disease. Part 2 will focus on the current and future therapeutics of this neurodegenerative condition. Produced by Travis Lewis and James E Siegler. Music by Azevedo Silva, Chris Zabriskie, Cullah, John Bartmann, and Nuno Adelaida. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES Bates GP, Dorsey R, Gusella JF, et al. Huntington disease. Nat Rev Dis Primers 2015;1:15005. PMID 27188817Ghosh R, Tabrizi SJ. Huntington disease. Handb Clin Neurol 2018;147:255-78. PMID 29325616Reilmann R, Leavitt BR, Ross CA. Diagnostic criteria for Huntington's disease based on natural history. Mov Disord 2014;29(11):1335-41. PMID 25164527Walker RH. Chorea. Continuum (Minneap Minn) 2013;19(5 Movement Disorders):1242-63. PMID 24092289Wild EJ, Tabrizi SJ. The differential diagnosis of chorea. Pract Neurol 2007;7(6):360-73. PMID 18024776 We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

Guest editor Dr. Ruth Walker kicks off this special series on chorea by interviewing Prof. Joseph Jankovic on the phenomenology and his approach to the clinical examination of the patient with chorea.

Max Weissensteiner trägt eine tödlich endende Erbkrankheit in sich: Chorea Huntington. Wie seine Großmutter und seine Mutter. Die Krankheit zerstört nach und nach die Zellen im Gehirn. „Mich kann nichts mehr so leicht umhauen“, sagt Max Weissensteiner. Der 33-Jährige sitzt in seiner 45 Quadratmeter-Wohnung im 17. Wiener Gemeindebezirk. Dort, wo einst die Vorstadt angekommen ist, die Gassen ruhiger werden und die Altbauten nicht ganz so hoch in den Himmel ragen. „Chorea kommt vom griechischen Wort für Tanz“, sagt Max. „Denn ein Teil der Symptome sind starke Bewegungsstörungen, die an tanzähnliche Bewegungen erinnern. Veitstanz ist ein alter Name. Das waren auch Symptome, die man bei meiner Oma gesehen hat.“ Mit der Oma und der Uroma und seiner Mama wächst Max in Ybbsitz, in Niederösterreich, auf. Es ist Anfang der 1990er-Jahre, als sich bei seiner Oma erste Symptome zeigen: Stimmungsschwankungen. Nach und nach kommen Bewegungseinschränkungen dazu. Stricken, Kochen, Essen, das alles geht nicht mehr so wie vorher: „Meine Oma war die erste in der Familie, wo sichtbar wurde, dass da etwas ist“, sagt Max. Anfang 50 ist die Oma damals, Max selbst gerade mal ein Jahr alt. Als Symptome und Ratlosigkeit in der Familie immer stärker werden, bringt ein Neurologe in Amstetten die Gewissheit: „Da ist zum ersten Mal dieser Name im Raum gestanden. Chorea Huntington. Neurodegenerativ. Vererbbar. Und unheilbar", sagt Weissensteiner. „Es ist, als ob man damit in einen neuen Lebensabschnitt tritt. Plötzlich war die Krankheit Teil unserer Familiengeschichte.“ Wie mit diesem Wissen leben? Max' Antwort: Sich immer wieder fragen, was mir wirklich wichtig ist. Jetzt. Eine Sendung von Gerlinde Petric-Wallner.(DaCapo: Mittwoch, 13. März um 21 Uhr) INFOS: Liebe zur Musik:Unter dem Künstlernamen Willibald Schneider hat Max Weissensteiner vor kurzem eine neue Single herausgebracht: "3341". Sie ist seinem Heimatort Ybbsitz gewidmet.Zu hören und sehen HIER.Gemeinschaft:Unterstützung findet Max Weissensteiner auch im Verein Conscious Brothers: Der Verein setzt sich für eine neue Form der Männlichkeit und konstruktive Rollenbilder ein.Chorea Huntington:Österreichische Huntington-Hilfe

„Meine Mutter war nicht mehr meine Mutter“, sagt Marco Schreyl. Der TV- und Rundfunkmoderator und Journalist hat in der eigenen Familie erlebt, wie die Huntington-Erkrankung die Persönlichkeit eines Menschen verändern kann: Seine Mutter war an der seltenen, neurodegenerativen Krankheit erkrankt und ist im Alter von nur 65 Jahren daran verstorben. Betroffen sind bei Huntington neben der Bewegung auch die Psyche der Betroffenen sowie die kognitiven Fähigkeiten. Die bislang unheilbare Nervenkrankheit ist genetisch, also erblich bedingt. Direkte Nachkommen von Huntington-Erkrankten haben ein 50-prozentiges Risiko, ebenfalls zu erkranken. Im Gespräch mit Moderatorin Sabine Heinrich erzählt Marco Schreyl, wie er bereits vor der Diagnose merkte, dass etwas nicht mit seiner einst so warmherzigen, empathischen Mutter stimmte und dass sie ihre Empathie verloren hatte – für sich selbst und für ihre Umgebung. Über ihre Huntington-Erkrankung und seinen Umgang damit hat er nach dem Tod seiner Mutter ein Buch geschrieben. Im Podcast berichtet Marco Schreyl, wie ihm das Buch geholfen hat, das Erlebte zu verarbeiten. Er spricht mit Sabine Heinrich auch darüber, warum er sich bislang dagegen entschieden hat, durch einen Gentest erfahren zu können, ob er selbst Genträger ist und früher oder später erkranken wird. Zuhörende erfahren außerdem, wie Angehörige von Betroffenen auf die eigenen Bedürfnisse achten können.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question. In this episode, we're covering the recent expanded indication of valbenazine (Ingrezza; Neurocrine Biosciences) to include the treatment of chorea associated with Huntington disease (HD). Erin Furr-Stimming, MD, FAAN, FANA, a professor of neurology at McGovern Medical School of UTHealth Houston, and principal investigator of the phase 3 KINECT-HD studies, valbenazine's supportive studies, offered her immediate reaction to the news. In addition, she spoke about the efficacy observed in these trials, the advantages valbenazine has as a VMAT2 inhibitor, and the remaining unmet needs in the management of HD.   For more of NeurologyLive®'s coverage of valbenazine's expanded indication, head here: FDA Approves Neurocrine Biosciences' Valbenazine for Huntington Disease Chorea Episode Breakdown: 0:30 – Valbenazine approved for Huntington disease chorea 1:35 – Erin Furr-Stimming, MD, FAAN, FANA, on immediate reaction 2:15 – Treatment toolbox for HD chorea  3:05 – Furr-Stimming on mechanistic advantages of valbenazine 5:10 – Phase 3 efficacy data of valbenazine 5:55 – Furr-Stimming on greatest clinical takeaways from trials 6:55 – Current state of Huntington management 8:00 – Furr-Stimming on current unmet needs for patients, including research on disease-modifying therapies Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Neurocrine Biosciences Announces FDA Approval of INGREZZA® (valbenazine) Capsules for the Treatment of Chorea Associated With Huntington's Disease. News Release. Neurocrine Biosciences. Published August 18, 2023. Accessed August 21, 2023.

In Part 3 of a 3-part series, Dr. Erin Furr-Stimming discusses her article, "Chorea" from the October Continuum Movement Disorders issue.  Show references: Chorea - Continuum Journal  This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

In Part 2 of a 3-part series, Dr. Erin Furr-Stimming discusses her article, "Chorea" from the October Continuum Movement Disorders issue.  Show references: Chorea - Continuum Journal  This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

In Part 1 of a 3-part series, Dr. Erin Furr-Stimming discusses her article, "Chorea" from the October Continuum Movement Disorders issue.  Show references: Chorea - Continuum Journal  This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.

In part 5 of a 5 part series, Dr. Vikram Karnik discusses the approach to adult-onset chorea.

In part 4 of a 5 part series, Dr. Vikram Karnik discusses the approach to adult-onset chorea.

In part 3 of a 5 part series, Dr. Vikram Karnik discusses the approach to adult-onset chorea.

In part 2 of a 5 part series, Dr. Vikram Karnik discusses the approach to adult-onset chorea.

In part 1 of a 5 part series, Dr. Vikram Karnik discusses the approach to adult-onset chorea.

Quizmasters Lee and Marc meet with Chef Skyler Denison (Death by Taco 239) for a general knowledge quiz on Food, Conspiracy Theories, Ancient History, Football , Music, Movies, Cartoons and more! Round One ANIMALS - George Washington introduced America to what animal of which Darwin wrote, "Always appears to me so surprising that a hybrid should possess more reason, memory, obstenency, social affection, powers of muscular endurance and length in life than either of its parents, seems to indicate that art here has outdone nature?" BEAVIS AND BUTTHEAD - Which two band's shirts are frequently worn by Beavis and Butthead (and who wears what)? SONG TITLES - Due to the original name sounding too much like a cuss word, "Green Onions" by Booker T and M.G.'s was first titled what? MOVIE CHARACTERS - What is the name of the horse in The Neverending Story? FOOD INVENTIONS - What kind of Italian loaf was invented in 1982 as a response to the popularity of French baguettes? SEINFELD - Which Seinfeld main character, later appearing in 169 episodes, did not appear in the pilot episode? Round Two SEX AND THE CITY - When Samantha gets a chemical peel to look "fresh," Carrie agrees by saying she looks like what Italian meat dish that is typically served raw? PSYCHOLOGY - Sydenham's Chorea a disorder characterized by rapid uncoordinated jerking movements is oftentimes referred to as "The Dance of" what saint? POPULAR VEGETABLES - In the 1800's and early 1900's, which vegetable was the third most popular menu item in New York City, just after tea and coffee, often kept in a glass vase on the table to be salted and eaten raw? THE SMURFS - Which smurf is often seen in disputes with Brainy Smurf, and is known for their characteristic arm tattoo of a heart with an arrow through it? NFL RECORDS - Tom Brady broke NFL history recently with 602 regular season touchdown passes. Who has thrown the fourth most with 552? CONSPIRACY THEORIES - In 1992, a conspiracy theory surrounding Microsoft's Wingdings application started after the realization that character sequence of what popular major city's rendered a star of david, skull and crossbones, and thumbs up symbols? Rate My Question PUNK LYRICS - Jon Wurster, best known as the drummer of Superchunk as well as The Mountain Goats, was mentioned by name in a song released in 1988 by what American punk band? Final Questions ANCIENT HISTORY - During the battle of Gaugamela, King Darius of Persia sent Alexander the Great a bag of sesame seeds to symbolize the number of his troops. Alexander responded by sending what seed to symbolize a more potent and fiery army? U.S. HISTORY - July 6, 1944, is still remembered as "the day the clowns cried" due to a tragic circus fire in what Northeast capital city? PHYSICISTS - In 1922, what Danish, Nobel Prize winning physicist won a lifetime supply of beer from Carlsberg Brewing, as well as a permanent tap installed in his home from which to draw upon the supply? Upcoming LIVE Know Nonsense Trivia Challenges December 1st, 2021 - Know Nonsense Challenge - Point Ybel Brewing Co. - 7:30 pm EDT December 2nd, 2021 - Know Nonsense Trivia Challenge - Ollies Pub Records and Beer - 7:30 pm EDT You can find out more information about that and all of our live events online at KnowNonsenseTrivia.com All of the Know Nonsense events are free to play and you can win prizes after every round. Thank you Thanks to our supporters on Patreon. Thank you, Quizdaddies – Brandon, Issa, Adam V., Tommy (The Electric Mud) and Tim (Pat's Garden Service) Thank you, Team Captains – Captain Nick, Grant, Mo, Jenny, Rick G., Skyler, Dylan, Shaun, Lydia, Gil, David, Aaron, Kristen & Fletcher Thank you, Proverbial Lightkeepers – Robb, Rachael, Rikki, Jon Lewis, Moo, Tim, Nabeel, Patrick, Jon, Adam B., Ryan, Mollie, Lisa, Alex, Spencer, Kaitlynn, Manu, Matthew, Luc, Hank, Justin, Cooper, Elyse, Sarah, Karly, Kristopher, Josh, Lucas Thank you, Rumplesnailtskins – Sarah, FoxenV, Laurel, A-A-Ron, Loren, Hbomb, Alex, Doug, Kevin and Sara, Tiffany, Allison, Paige, We Do Stuff, Kenya, Jeff, Eric, Steven, Efren, Mike J., Mike C., Mike. K If you'd like to support the podcast and gain access to bonus content, please visit http://theknowno.com and click "Support." Special Guest: Skyler Denison.

Chorea Huntington, auch „Huntington-Krankheit“ oder „Morbus Huntington“ genannt, ist eine seltene, aber tödlich verlaufende Erkrankung des Gehirns. Die Huntington-Krankheit hat genetische, also erbliche Ursachen und ist bislang unheilbar. Sie kann sowohl im Kindesalter bis zum hohen Alter ausbrechen. Zu den Symptomen zählen unwillkürliche zuckende Bewegungen und ein charakteristischer tänzelnder Gang: Deshalb wurde die Krankheit früher „Veitstanz“ genannt. Auch der Begriff „Chorea“ stammt vom griechischen Wort „choreia“ für „Tanz“. Die Huntington-Krankheit ist aber weit mehr als eine Bewegungsstörung: Im Gehirn von Menschen mit Morbus Huntington gehen nach und nach Bereiche zugrunde, die nicht nur für die Steuerung der Muskeln, sondern auch für psychische und kognitive Funktionen wichtig sind. Was passiert mit Körper und Psyche der Erkrankten? Was weiß man über die erblichen Ursachen? Wie ist der aktuelle Stand der Forschung? Diese und andere Fragen rund um Morbus Huntington bespricht die Journalistin Sabine Heinrich mit dem Neurologen Prof. Dr. Albert Ludolph. Er ist Standortsprecher am DZNE Ulm und Ärztlicher Direktor der Neurologischen Klinik am RKU – Universitäts- und Rehabilitationskliniken Ulm. Im Podcast spricht der Spezialist für seltene neurodegenerative Erkrankungen über frühe Huntington-Anzeichen wie Verhaltensstörungen, Depressionen oder Wahnvorstellungen (Psychosen) und erklärt, ob man den Verlauf der Erbkrankheit hinauszögern kann.

Professor Javier Fernández-Ruiz is Professor in the Department of Biochemistry and Molecular Biology, Faculty of Medicine at the Complutense University of Madrid. He is currently the Principal Investigator of the “Cannabinoids and Neurological Disorders” research group at the Complutense University. Professor Fernandez is also a member of the Editorial Board in the British Journal of Pharmacology. He has authored several papers outlining the therapeutic potential of cannabinoids in degenerative disorders including:Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical ApplicationsEndocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and OthersCannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomesProspects for cannabinoid therapies in basal ganglia disordersAs Professor Fernandez mentioned in the podcast, he is happy to be contacted by anyone interested in finding out more about his area of research and can be emailed on jjfr@med.ucm.es. (Please remember he is not a medical doctor). Support the show (https://www.paypal.com/paypalme/marybiles71)

In medieval Strasbourg, during a period of unimaginable suffering and poverty, a mania took hold. Infected people were gripped by the compulsion to dance in the streets until they dropped senseless from exhaustion - or died. When the strange illness began to spread, the city took a series of steps to help the afflicted, culminating in a thirty-mile trek to seek the intervention of an obscure saint who may or may not have been angry at the city's sinful lifestyle. On this episode, we look at the time period leading up to the dancing plague, possible causes, how it spread, what the cure looked like (it came with a free pair of red shoes!) and what made this event so much worse than similar ones across the late Middle Ages. Sources for this episode include: “The Dancing Mania: The Strange, True Story of an Extraordinary Illness”, J. Waller, 2009 “The Black Death and the Dancing Mania”, J F K Hecker, (Babington translation), 1856 “The Differential Diagnosis of Chorea”, E J Wild et al, published in ‘Practical Neurology', 2007 “The Dancing Plague of the Middle Ages”, M. Petcova, published in ‘Medium', 2020 “Dancing Plagues and Mass Hysteria”, J Waller, published in ‘The Psychologist' (British Psychological Society), 2009

This special edition of the Mixtape Tales podcast is a discussion of Huntington's Disease with my cousin, Amanda. She talks about the testing process, why advocacy is crucial, and shares her -- OUR -- family story. I am titling these episodes "Talking Chorea Blues" in honor of an unrecorded Woody Guthrie song related to his illness. In case you were wondering where the title came from :) If you want to tell your family's HD story, shoot me an email pbriggs1977@gmail.com and we will set up a time to talk. I can not thank Amanda enough for taking the time to do this, and I hope you find her episode informative and helpful.

Wikipedia

Aus der Wikipedia

Chorea is a sixth level enchantment cast upon the self with a material requirement of ergot fungi and a duration that will last until the fungi is burned with lavender flowers.  Chorea is a rare, contagious spell that will spread it’s effects to anyone who makes physical contact. Chorea causes one to have an irresistible desire to dance.  The movement can be as subtle as tapping a foot or wildly acrobatic.  The target feels euphoric, and after the spell ends, they feel refreshed.  Chorea was discovered in July 1518 in France.  However, the method for ending the spell was not discovered until the 1800s.  On that Summer day centuries ago, Frau Troffea, of Strasbourg, unwittingly cast the spell upon herself and began to dance.  This lasted somewhere between four and six days. Within a week, 34 others had joined, and within a month, there were around 400 dancers, predominantly female. All these people died from heart attacks, strokes, or exhaustion.  The plague ended after the final dancer had died before touching another person. Today, the spell is used as a recreational drug. The use of chorea is legal in 39 states so long as a thurible is used.  A thurible is a tall candle holder with a timer that drops the fungi and lavender into the flame.  There are currently eleven states where chorea is banned.  Check local laws before casting.

A questioned-based review of hyperkinetic movement disorders of childhood with emphasis on Tics (primary and 2ndary) and Tourette syndrome as well as stereotypies (as important differential diagnosis of Autism Spectrum Disorder) including Rett Syndrome (X-linked Dominant developmental regression) followed by a brief discussion of important differentials of Chorea, Myoclonus and Dystonia Subjects are important for USMLE Steps 1,2, 3

Dr. Vikram Karnik discusses the pharmacologic treatment of chorea in Huntington's disease. Show references: https://n.neurology.org/content/pharmacologic-treatment-chorea-huntington-disease https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842832/  

Dr. Fabio Nascimento discusses the movement disorder chorea.

Wykład profesor Anny Wyki o kulturze alternatywnej w Polsce, Collegium Civitas [8 listopada 2009 r.] Wykład przeprowadzony 8 listopada 2009 r. w Collegium Civitas w ramach cyklu „Współczesne społeczeństwa: Polska – Europa – Świat. Kultura, mentalność, system wartości.” Kultura alternatywna zaczęła pojawiać się w Polsce w latach 70. U jej podłoża leżą m.in. kontrast między światem zewnętrznym i rzeczywistym, dotkliwy w okresie PRLu, chęć rozwoju wewnętrznego, docenianie wartości kontaktów międzyludzkich, poczucie jedności z naturą, indywidualna sprawczość, a także kwestionowanie wartości posiadania dóbr, na rzecz głębszego rozwoju. Rozwój kultury alternatywnej podzielić można na trzy etapy. Pierwsza faza to moment negacji, przy jednoczesnym braku świadomości współodczuwania tej negacji przez innych ludzi, w drugiej fazie pojawia się poczucie wspólnoty, trzeci etap jest fazą w której wspólne wartości są znane i prowadzą do proponowania alternatywy i konstruktywnych działań. Indywidualne podejście i stawianie na rozwój jednostki, sprawiły że wytworzył się alternatywny styl życia, w którym dążono do spójności między wyznawanymi wartościami, a ich realizacją. Było to przeciwstawienie się rzeczywistości powojennego świata. Głód wartości duchowych, chęć reedukacji, dezalienacji i samorealizacji, uwzględniającej dobro drugiego człowieka, prowadziły do powstania grup i komun wspierających swoje działania. Ważną postacią skupiającą poszukujących alternatywy był Jerzy Grotowski. Kontynuatorami praktyki kultury czynnej i twórczego stosunku do życia i działalności, jest wiele działających nadal środowisk m.in. Ośrodek „Pogranicze – sztuk, kultur, narodów”, Fundacja „Muzyka Kresów”, Stowarzyszenie „Tratwa”, a także teatry: Studium Teatralne, Chorea, Teatr Wiejski Węgajty, Gardzienice. Wykład nakreśla powstanie kultury alternatywnej i jej losy na przestrzeni dekad, aż do dnia dzisiejszego. Pokazuje najważniejsze idee, praktyki, cechy i motywy powstawania ruchów alternatywnych. Przybliża postaci ważne dla alternatywnej kultury m. in. działalność i poglądy Jerzego Grotowskiego.

Chorea is a sixth level enchantment cast upon the self with a material requirement of ergot fungi and a duration that will last until the fungi is burned with lavender flowers.  Chorea is a rare, contagious spell that will spread it’s effects to anyone who makes physical contact. Chorea causes one to have an irresistible desire to dance.  The movement can be as subtle as tapping a foot or wildly acrobatic.  The target feels euphoric, and after the spell ends, they feel refreshed.  Chorea was discovered in July 1518 in France.  However, the method for ending the spell was not discovered until the 1800s.  On that Summer day centuries ago, Frau Troffea, of Strasbourg, unwittingly cast the spell upon herself and began to dance.  This lasted somewhere between four and six days. Within a week, 34 others had joined, and within a month, there were around 400 dancers, predominantly female. All these people died from heart attacks, strokes, or exhaustion.  The plague ended after the final dancer had died before touching another person. Today, the spell is used as a recreational drug. The use of chorea is legal in 39 states so long as a thurible is used.  A thurible is a tall candle holder with a timer that drops the fungi and lavender into the flame.  There are currently eleven states where chorea is banned.  Check local laws before casting.

In this episode I cover Huntington's chorea.If you want to follow along with written notes on Huntington's chorea go to https://zerotofinals.com/medicine/neurology/huntingtonschorea/ or the neurology section in the Zero to Finals medicine book.This episode covers pathophysiology, presentation, diagnosis and management of Huntington's chorea.The audio in the episode was expertly edited by Harry Watchman.

Bailamos de un extremo al otro del mundo en esta edición de Mundofonías, con evocaciones de los cinco continentes y noticias de festivales que estos días nos tientan: Czech Music Crossroads, Festival Músicas do Mundo de Sines, Pirineos Sur, Etnosur, La Mar de Músicas... We dance from end to end of the world in this Mundofonías edition, with evocations from the five continents and some news about ongoing festivals: Czech Music Crossroads, Festival Músicas do Mundo de Sines, Pirineos Sur, Etnosur, La Mar de Músicas... · Orchestra Bailam & Canterini Genovesi - Ninte de bon - Trallalero levantin · Huun Huur Tu & Anewal - Tamiditin / Bolur daa bol - Nomads' roots · Sam Lee, Notes Inégales, Peter Wiegold - Suit of blue - Van Diemen's Land · S?UK  - Ouvertúra - Chorea slovaca (Tane?né etudy pre S?UK) · Milli Janatková - Buoh / God - [cortesía de / courtesy of: Czech Music Crossroads] · Miriam Kaiser Trio - Tanec strún - Tanec strún · Vaudou Game - Lucie - Otodi · Orquesta Akokán - La corbata barata - Orquesta Akokán (The instrumentals) · Mayalde - La regadera (mazurca) - N´ca Mayalde Imagen /Image: Orchestra Bailam

Dr. Mered Parnes discusses with Dr. Sara Schaefer his article on benign hereditary chorea recently published in the January 2019 issue of the Movement Disorders Clinical Practice.

Orden dans och pest framkallar två motstridiga känslor. Ändå är det så historieböckerna väljer att beskriva det som tidvis inträffade i medeltidens Europa. Upphovsmannen till denna pest, i Strasbourg anno 1518, var varken en man eller en svartråtta. Dansen var inte behaglig för de som utövade den eller vacker att se på. När läkarna har uteslutit allt som är omöjligt så måste det som återstår, oavsett hur osannolikt det är, vara sanningen.

You may be able to recognize chorea. But what does it make you think of besides Huntington Disease? In this two part series, we'll cover the clinical manifestations, differential diagnosis, and management of Huntington Disease. In part 1, Dr. Travis Lewis (University of Pennsylvania) creates a framework for hyperkinetic movement disorders and HD. Part 2 will focus on the current and future therapeutics of this neurodegenerative condition. Produced by Travis Lewis & James E. Siegler. Music by Azevedo Silva, Chris Zabriskie, Cullah, John Bartmann, and Nuno Adelaida. Sound effects by Mike Koenig and Daniel Simion. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. Be sure to follow us on Twitter @brainwavesaudio for the latest updates to the podcast. REFERENCES Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ and Tabrizi SJ. Huntington disease. Nat Rev Dis Primers. 2015;1:15005. Wild EJ and Tabrizi SJ. The differential diagnosis of chorea. Pract Neurol. 2007;7:360-73. Walker RH. Chorea. Continuum (Minneap Minn). 2013;19:1242-63. Reilmann R, Leavitt BR and Ross CA. Diagnostic criteria for Huntington's disease based on natural history. Mov Disord. 2014;29:1335-41. Ghosh R and Tabrizi SJ. Huntington disease. Handbook of clinical neurology. 2018;147:255-278.

Do trzeciego odcinka zaprosiłem Teatr CHOREA. Dwóch przedstawicieli opowiada o historii, o teatrze oraz o znaczeniu słów "aktor" i "teatr" dla nich. Oprócz części typowej dla każdego pokastu, goście przygotowali dwa ćwiczenia z książki: "Trening fizyczny aktora - Od działań indywidualnych do zespołu", o której więcej dowiecie się słuchając odcinka w całości. Link do zakupu książki: https://bit.ly/2N3TZjJ Strona Teatru: http://www.chorea.com.pl/ Facebook CHOREI: https://web.facebook.com/choreateatr/?_rdc=1&_rdr Zapraszam również do polubienia strony podkastu na Facebooku: fb.me/kulturalniepodkast E-mail: kulturalniepodcast@aol.com Jeśli używasz aplikacji mobilnej Anchor, to zostaw gwiazdkę lub wyślij wiadomość głosową. RSS podkastu: anchor.fm/s/26742a4/podcast/rss Muzyka: SHE-la "Ultimate Answer"

After clinical trial results were announced for deutetrabenazine (Austedo), I hoped we might be getting a drug that didn't cause the side effects of other chorea treatments (antipsychotics or the old tetrabenazine). And now that I have prescribed it, it has proved better than I had expected based on the clinical trial results.  Though not successful in everyone, it has clearly decreased chorea in most. But what I was not expecting is how much this drug improves the functional activities that chorea impacted. (Part of Dr. Goodman's Article on Austedo on HD Drugworks) To read the whole article please go to: http://hddrugworks.org/

This week we don't necessarily dive into one particular disease or disorder, but a neurological symptom that is seen in various diseases. We know a bit about how Chorea works, but what exactly is it? how do we see it in various diseases? what can we do to alleviate its effects? Join us this week, with a new special guest introducer!

Samuel Frank, MD,is an associate professor of Neurology at Beth Israel Deaconess Medical Center and Harvard Medical School. After completing his residency and fellowship at the University of Rochester, he joined the neurology faculty at Boston University from 2004 to 2015. Dr. Frank is an active member of the Huntington Study Group, having served as a principal investigator and as a member of HSG’s executive committee. He has also served as a member of HDSA’s Board of Trustees and is the director of the HDSA Center of Excellence at Beth Israel Deaconess Medical Center. Dr. Frank is the inpatient neurology consultant for the specialized Huntington’s Disease service at Tewksbury Hospital. Dr. Frank was the principal investigator for First-HD, a Phase 3 clinical trial investigating deuterated tetrabenazine as a possible treatment for chorea associated with HD. Last week, the FDA approved the new drug based on positive results from the First-HD trial, which was led by the Huntington Study Group (HSG) on behalf of Teva Pharmaceuticals. 

Tonight Dr. Samuel Frank of the Huntington Study Group (HSG) discusses TEVA's new drug - AUSTEDO for the treatment of chorea in Huntington's disease. There will be questions from the community! #YouAreLoved

Tonight Dr. Samuel Frank of the Huntington Study Group (HSG) discusses TEVA's new drug - AUSTEDO for the treatment of chorea in Huntington's disease. There will be questions from the community! #YouAreLoved

Teufelsdroge? - Wie gefährlich Crystal Meth ist / Googles selbstfahrendes Auto - Unfall wegen fehlerhafter Software? / Staudämme als Waffe - Wie der IS mit Wasser Krieg führt / Erbkrankheit Chorea Huntington - Neue Hoffnung für Patienten?

Chorea-Acanthocytosis: ChAc is a rare progressive neurological disorder caused by mutations in a very complex gene. Dr Antonio Velayos-Baeza is interested in two main projects: Chorea-acanthocytosis (ChAc), a rare autosomal-recessive disorder that is characterised by progressive neurodegeneration and red cell acanthocytosis (spiky red blood cells), and Developmental dyslexia, the most common of the childhood learning disorders.

Chorea-Acanthocytosis: ChAc is a rare progressive neurological disorder caused by mutations in a very complex gene. Dr Antonio Velayos-Baeza is interested in two main projects: Chorea-acanthocytosis (ChAc), a rare autosomal-recessive disorder that is characterised by progressive neurodegeneration and red cell acanthocytosis (spiky red blood cells), and Developmental dyslexia, the most common of the childhood learning disorders.

Thu, 10 Apr 2014 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/19358/ https://edoc.ub.uni-muenchen.de/19358/1/Liu_Jia.pdf Liu, Jia ddc:610, ddc:600, Medizinische Fakultät

MDS presents the latest research and findings from the field of Movement Disorders. Abstracts of articles from the Society Journal, Movement Disorders, are taken from the February 2014 (Vol. 29, Issue 2) issue.

MDS presents the latest research and findings from the field of Movement Disorders. Abstracts of articles from the Society Journal, Movement Disorders, are taken from the January 2014 (Vol. 29, Issue 1) issue.

PRE-RECORDED -- MONDAY, September 17, 2012 In direct response to a previous show with Dr. LaVonne Goodman and information disseminated about the AAN (the American Academy of Neurology) Guidelines for Treating Chorea in Huntington's, (see report) Melissa Armstrong, MD, MSc and Gary Gronseth, MD, FAAN are here today to explain how the AAN Clinical Practice Guideline process works to deliver the best evidence-based recommendations to physicians who are treating for neurological disorders, in particular chorea in Huntington's disease. For more information about the American Academy of Neurology, visit www.aan.com.   We are honored, delighted and thrilled to have the prestigious American Academy of Neurology here with us today… About the AAN The American Academy of Neurology (AAN), established in 1948, is an international professional association of more than 25,000 neurologists and neuroscience professionals dedicated to promoting the highest quality patient-centered neurologic care.  

TUESDAY, September 4, 2012 It's time for the Ask Dr. Goodman show. Get your questions ready for another hour with our incredible Internist LaVonne Goodman. www.HDdrugworks.org

MONDAY, MARCH 5, 2012 at 3:30 pm PST/6:30 pm EST It's time for The HD View ~ Ask Dr. Goodman Show!   Tonight we get to welcome back the esteemed Dr. LaVonne Goodman, Internist and owner of www.HDDrugworks.org, which she founded with her husband Nathan Goodman where at present their focus is providing information on present treatment options for Huntington's disease.    She says, “when I began taking care of Huntington's disease (HD) patients, I looked for standard of care guides to help me provide quality medical care.  What I found was lack of information…”    Dr. Goodman authored the original Treatment Guidelines for Huntington's disease. A “Symptom Survivor” Guideline and Treatment guidelines for HD Obsessive Compulsive Behaviors, Irritability and Chorea. Find the original guidelines at www.WeHaveAfFce.org/HDDW.   Tonight we are going to talk specifically about numerous symptoms and treatments for Huntington's disease. We welcome your questions either by email message through my website www.Help4HD-International.org or through the Help 4 HD chat room during the live broadcast.   NOW IS THE TIME TO ASK ABOUT DRUGS AND TREATMENTS FOR HUNTINGTON'S DISEASE...

Sun, 1 Jan 2012 12:00:00 +0100 http://jnnp.bmj.com/content/83/Suppl_2/A14.4.abstract?sid=ccc27018-25b8-4eae-8af8-c02e427d8cf0 https://epub.ub.uni-muenchen.de/20879/1/oa_20879.pdf Radunovic, A.; Page, S.; Early, M.; Bader, B.; Danek, A.; Mohiddin, S.; Chan, J.; Fiddes, B.; Williamson, J. ddc:610, Medizin

Professor Jenny Morton provides new insight into the cognitive abilities of the supposedly dim-witted sheep and explains how these quick learning animals can be used to model Huntington's Disease... Like this podcast? Please help us by supporting the Naked Scientists

Professor Jenny Morton provides new insight into the cognitive abilities of the supposedly dim-witted sheep and explains how these quick learning animals can be used to model Huntington's Disease... Like this podcast? Please help us by supporting the Naked Scientists

Our special guest tonight is Daniel Brennan who joined Lundbeck in July 2009, after Xenazine had been developed and launched in the USA. He is Vice President and General Manager of Neurology Franchise at Lundbeck and now leads the group of people that distribute, provide information, and support Xenazine as well as other nervous system therapies for rare diseases. He enjoys meeting people in the HD community to better understand the impact that this disease has on people and their families, as well as learn what they can do better as a company as they continue to make the medicine available to the public. Lundbeck has become very involved and dedicated to Huntington's Disease and recently announced their commitment to research for HD that may halt or slow the progression of the disease. He'd like to make sure that he understands your concerns and also try to provide information that may be helpful in your understanding of Lunbeck's actions and activities.